{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:30:25Z","timestamp":1792189825101,"version":"4.4.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:00:00Z","timestamp":1580428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:00:00Z","timestamp":1580428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>High dose interleukin-2 (IL-2) is active against metastatic melanoma and renal cell carcinoma, but treatment-associated toxicity and expansion of suppressive regulatory T cells (Tregs) limit its use in patients with cancer. Bempegaldesleukin (NKTR-214) is an engineered IL-2 cytokine prodrug that provides sustained activation of the IL-2 pathway with a bias to the IL-2 receptor CD122 (IL-2R\u03b2). Here we assess the therapeutic impact and mechanism of action of NKTR-214 in combination with anti-PD-1 and anti-CTLA-4 checkpoint blockade therapy or peptide-based vaccination in mice. NKTR-214 shows superior anti-tumor activity over native IL-2 and systemically expands anti-tumor CD8<jats:sup>+<\/jats:sup>T cells while inducing Treg depletion in tumor tissue but not in the periphery. Similar trends of intratumoral Treg dynamics are observed in a small cohort of patients treated with NKTR-214. Mechanistically, intratumoral Treg depletion is mediated by CD8<jats:sup>+<\/jats:sup>Teff-associated cytokines IFN-\u03b3 and TNF-\u03b1. These findings demonstrate that NKTR-214 synergizes with T cell-mediated anti-cancer therapies.<\/jats:p>","DOI":"10.1038\/s41467-020-14471-1","type":"journal-article","created":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T11:02:58Z","timestamp":1580468578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":167,"title":["Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy"],"prefix":"10.1038","volume":"11","author":[{"given":"Meenu","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiep","family":"Khong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Fa\u2019ak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah-Eddine","family":"Bentebibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise M. E.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent C.","family":"Chesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin A.","family":"Creasy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Andr\u00e9e","family":"Forget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Maria S.","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pazdrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1028-9920","authenticated-orcid":false,"given":"Binisha","family":"Karki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yared","family":"Hailemichael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Vianden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Vennam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uddalak","family":"Bharadwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Tweardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1317-9287","authenticated-orcid":false,"given":"Cara","family":"Haymaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantale","family":"Bernatchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimal","family":"Rajapakshe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4183-4939","authenticated-orcid":false,"given":"Cristian","family":"Coarfa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Hurwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Sznol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Hoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali","family":"Addepalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah H.","family":"Charych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Zalevsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Diab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem W.","family":"Overwijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,31]]},"reference":[{"key":"14471_CR1","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8, 1069\u20131086 (2018).","journal-title":"Cancer Discov."},{"key":"14471_CR2","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018).","journal-title":"Science"},{"key":"14471_CR3","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","volume":"17","author":"MB Atkins","year":"1999","unstructured":"Atkins, M. B. et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105\u20132116 (1999).","journal-title":"J. Clin. Oncol."},{"key":"14471_CR4","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1001\/jama.1994.03510360033032","volume":"271","author":"SA Rosenberg","year":"1994","unstructured":"Rosenberg, S. A. et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271, 907\u2013913 (1994).","journal-title":"JAMA"},{"key":"14471_CR5","doi-asserted-by":"publisher","first-page":"5610","DOI":"10.1158\/1078-0432.CCR-08-0116","volume":"14","author":"FO Smith","year":"2008","unstructured":"Smith, F. O. et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin. Cancer Res. 14, 5610\u20135618 (2008).","journal-title":"Clin. Cancer Res."},{"key":"14471_CR6","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1056\/NEJMoa1012863","volume":"364","author":"DJ Schwartzentruber","year":"2011","unstructured":"Schwartzentruber, D. J. et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 364, 2119\u20132127 (2011).","journal-title":"N. Engl. J. Med."},{"key":"14471_CR7","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1182\/blood-2005-06-2399","volume":"107","author":"M Ahmadzadeh","year":"2006","unstructured":"Ahmadzadeh, M. & Rosenberg, S. A. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107, 2409\u20132414 (2006).","journal-title":"Blood"},{"key":"14471_CR8","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1200\/JCO.2005.03.6830","volume":"24","author":"GC Cesana","year":"2006","unstructured":"Cesana, G. C. et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J. Clin. Oncol. 24, 1169\u20131177 (2006).","journal-title":"J. Clin. Oncol."},{"key":"14471_CR9","doi-asserted-by":"publisher","first-page":"7487","DOI":"10.1158\/0008-5472.CAN-07-0565","volume":"67","author":"S Wei","year":"2007","unstructured":"Wei, S. et al. Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res. 67, 7487\u20137494 (2007).","journal-title":"Cancer Res."},{"key":"14471_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1172\/JCI46266","volume":"124","author":"GC Sim","year":"2014","unstructured":"Sim, G. C. et al. IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. J. Clin. Invest 124, 99\u2013110 (2014).","journal-title":"J. Clin. Invest"},{"key":"14471_CR11","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/nri3156","volume":"12","author":"O Boyman","year":"2012","unstructured":"Boyman, O. & Sprent, J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 12, 180\u2013190 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"14471_CR12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4049\/jimmunol.134.1.157","volume":"134","author":"MT Lotze","year":"1985","unstructured":"Lotze, M. T., Frana, L. W., Sharrow, S. O., Robb, R. J. & Rosenberg, S. A. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J. Immunol. 134, 157\u2013166 (1985).","journal-title":"J. Immunol."},{"key":"14471_CR13","doi-asserted-by":"publisher","first-page":"11906","DOI":"10.1073\/pnas.1002569107","volume":"107","author":"C Krieg","year":"2010","unstructured":"Krieg, C., Letourneau, S., Pantaleo, G. & Boyman, O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc. Natl Acad. Sci. USA 107, 11906\u201311911 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"14471_CR14","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1158\/1078-0432.CCR-15-1631","volume":"22","author":"DH Charych","year":"2016","unstructured":"Charych, D. H. et al. NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clin. Cancer Res. 22, 680\u2013690 (2016).","journal-title":"Clin. Cancer Res."},{"key":"14471_CR15","doi-asserted-by":"publisher","first-page":"e0179431","DOI":"10.1371\/journal.pone.0179431","volume":"12","author":"D Charych","year":"2017","unstructured":"Charych, D. et al. Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy. PloS ONE 12, e0179431 (2017).","journal-title":"PloS ONE"},{"key":"14471_CR16","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1158\/2159-8290.CD-18-1495","volume":"9","author":"SE Bentebibel","year":"2019","unstructured":"Bentebibel, S. E. et al. A first-in-human study and biomarker analysis of NKTR-214, a novel IL2Rbetagamma-Biased cytokine, in patients with advanced or metastatic solid tumors. Cancer Disco. 9, 711\u2013721 (2019).","journal-title":"Cancer Disco."},{"key":"14471_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41591-018-0266-5","volume":"25","author":"W Scheper","year":"2019","unstructured":"Scheper, W. et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat. Med. 25, 89\u201394 (2019).","journal-title":"Nat. Med."},{"key":"14471_CR18","doi-asserted-by":"publisher","first-page":"238ra270","DOI":"10.1126\/scitranslmed.3008211","volume":"6","author":"E Cha","year":"2014","unstructured":"Cha, E. et al. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci. Transl. Med. 6, 238ra270 (2014).","journal-title":"Sci. Transl. Med."},{"key":"14471_CR19","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1084\/jem.20030590","volume":"198","author":"WW Overwijk","year":"2003","unstructured":"Overwijk, W. W. et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198, 569\u2013580 (2003).","journal-title":"J. Exp. Med."},{"key":"14471_CR20","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1172\/JCI93303","volume":"128","author":"Y Hailemichael","year":"2018","unstructured":"Hailemichael, Y. et al. Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. J. Clin. Invest. 128, 1338\u20131354 (2018).","journal-title":"J. Clin. Invest."},{"key":"14471_CR21","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nm.3105","volume":"19","author":"Y Hailemichael","year":"2013","unstructured":"Hailemichael, Y. et al. Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion. Nat. Med. 19, 465\u2013472 (2013).","journal-title":"Nat. Med."},{"key":"14471_CR22","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nature11538","volume":"490","author":"J Landsberg","year":"2012","unstructured":"Landsberg, J. et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 490, 412\u2013416 (2012).","journal-title":"Nature"},{"key":"14471_CR23","first-page":"7920","volume":"61","author":"MH Kershaw","year":"2001","unstructured":"Kershaw, M. H. et al. Immunization against endogenous retroviral tumor-associated antigens. Cancer Res. 61, 7920\u20137924 (2001).","journal-title":"Cancer Res."},{"key":"14471_CR24","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1074\/jbc.275.2.867","volume":"275","author":"H Asao","year":"2000","unstructured":"Asao, H. & Fu, X. Y. Interferon-gamma has dual potentials in inhibiting or promoting cell proliferation. J. Biol. Chem. 275, 867\u2013874 (2000).","journal-title":"J. Biol. Chem."},{"key":"14471_CR25","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/sj.onc.1205255","volume":"21","author":"S Fulda","year":"2002","unstructured":"Fulda, S. & Debatin, K. M. IFNgamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene 21, 2295\u20132308 (2002).","journal-title":"Oncogene"},{"key":"14471_CR26","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1634\/theoncologist.11-4-397","volume":"11","author":"R van Horssen","year":"2006","unstructured":"van Horssen, R., Ten Hagen, T. L. & Eggermont, A. M. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 11, 397\u2013408 (2006).","journal-title":"Oncologist"},{"key":"14471_CR27","doi-asserted-by":"publisher","first-page":"e16241","DOI":"10.1371\/journal.pone.0016241","volume":"6","author":"F Liu","year":"2011","unstructured":"Liu, F. et al. TNFalpha cooperates with IFN-gamma to repress Bcl-xL expression to sensitize metastatic colon carcinoma cells to TRAIL-mediated apoptosis. PloS ONE 6, e16241 (2011).","journal-title":"PloS ONE"},{"key":"14471_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1089\/jir.1994.14.49","volume":"14","author":"M Hori","year":"1994","unstructured":"Hori, M., Kamijo, R., Takeda, K. & Nagumo, M. Downregulation of c-myc expression by tumor necrosis factor-alpha in combination with transforming growth factor-beta or interferon-gamma with concomitant inhibition of proliferation in human cell lines. J. Interferon Res. 14, 49\u201355 (1994).","journal-title":"J. Interferon Res."},{"key":"14471_CR29","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1111\/febs.13656","volume":"283","author":"C Liu","year":"2016","unstructured":"Liu, C., Workman, C. J. & Vignali, D. A. Targeting regulatory T cells in tumors. FEBS J. 283, 2731\u20132748 (2016).","journal-title":"FEBS J."},{"key":"14471_CR30","doi-asserted-by":"crossref","unstructured":"Chaudhary, B. & Elkord, E. Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting. Vaccines (Basel) 4,\u00a0E28\u00a0(2016).","DOI":"10.3390\/vaccines4030028"},{"key":"14471_CR31","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1084\/jem.20130579","volume":"210","author":"TR Simpson","year":"2013","unstructured":"Simpson, T. R. et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med 210, 1695\u20131710 (2013).","journal-title":"J. Exp. Med"},{"key":"14471_CR32","doi-asserted-by":"crossref","unstructured":"Sharma, A. et al. Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers. Clin. Cancer Res. 25, 3468 (2018).","DOI":"10.1158\/1078-0432.CCR-18-3740"},{"key":"14471_CR33","doi-asserted-by":"publisher","first-page":"14987","DOI":"10.1073\/pnas.0806075105","volume":"105","author":"CI Liakou","year":"2008","unstructured":"Liakou, C. I. et al. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc. Natl Acad. Sci. USA 105, 14987\u201314992 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"14471_CR34","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.cell.2017.05.005","volume":"169","author":"AE Overacre-Delgoffe","year":"2017","unstructured":"Overacre-Delgoffe, A. E. et al. Interferon-gamma drives treg fragility to promote anti-tumor immunity. Cell 169, 1130\u20131141 e1111 (2017).","journal-title":"Cell"},{"key":"14471_CR35","doi-asserted-by":"publisher","first-page":"8700","DOI":"10.1158\/0008-5472.CAN-09-1145","volume":"69","author":"X Cao","year":"2009","unstructured":"Cao, X. et al. Interleukin 12 stimulates IFN-gamma-mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance. Cancer Res. 69, 8700\u20138709 (2009).","journal-title":"Cancer Res."},{"key":"14471_CR36","doi-asserted-by":"crossref","unstructured":"Shelke, G. V. et al. TNF-alpha and IFN-gamma together up-regulates Par-4 expression and induce apoptosis in human neuroblastomas. Biomedicines,\u00a06, E4 (2017).","DOI":"10.3390\/biomedicines6010004"},{"key":"14471_CR37","first-page":"311","volume":"18","author":"R Matsumura","year":"2000","unstructured":"Matsumura, R. et al. Interferon gamma and tumor necrosis factor alpha induce Fas expression and anti-Fas mediated apoptosis in a salivary ductal cell line. Clin. Exp. Rheumatol. 18, 311\u2013318 (2000).","journal-title":"Clin. Exp. Rheumatol."},{"key":"14471_CR38","doi-asserted-by":"publisher","first-page":"4481","DOI":"10.4049\/jimmunol.166.7.4481","volume":"166","author":"K Suk","year":"2001","unstructured":"Suk, K. et al. IFN-gamma\/TNF-alpha synergism as the final effector in autoimmune diabetes: a key role for STAT1\/IFN regulatory factor-1 pathway in pancreatic beta cell death. J. Immunol. 166, 4481\u20134489 (2001).","journal-title":"J. Immunol."},{"key":"14471_CR39","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-018-0020-8","volume":"18","author":"G Gaud","year":"2018","unstructured":"Gaud, G., Lesourne, R. & Love, P. E. Regulatory mechanisms in T cell receptor signalling. Nat. Rev. Immunol. 18, 485\u2013497 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"14471_CR40","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/emm.2007.14","volume":"39","author":"YR Lee","year":"2007","unstructured":"Lee, Y. R. et al. TNF-alpha upregulates PTEN via NF-kappaB signaling pathways in human leukemic cells. Exp. Mol. Med 39, 121\u2013127 (2007).","journal-title":"Exp. Mol. Med"},{"key":"14471_CR41","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.4049\/jimmunol.1302379","volume":"193","author":"C Wu","year":"2014","unstructured":"Wu, C. et al. IFN-gamma primes macrophage activation by increasing phosphatase and tensin homolog via downregulation of miR-3473b. J. Immunol. 193, 3036\u20133044 (2014).","journal-title":"J. Immunol."},{"key":"14471_CR42","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1158\/2326-6066.CIR-14-0095","volume":"2","author":"R Abu-Eid","year":"2014","unstructured":"Abu-Eid, R. et al. Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway. Cancer Immunol. Res 2, 1080\u20131089 (2014).","journal-title":"Cancer Immunol. Res"},{"key":"14471_CR43","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nature13444","volume":"510","author":"K Ali","year":"2014","unstructured":"Ali, K. et al. Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 510, 407\u2013411 (2014).","journal-title":"Nature"},{"key":"14471_CR44","first-page":"2521","volume":"116","author":"PT Walsh","year":"2006","unstructured":"Walsh, P. T. et al. PTEN inhibits IL-2 receptor-mediated expansion of CD4+ CD25+ Tregs. J. Clin. Invest 116, 2521\u20132531 (2006).","journal-title":"J. Clin. Invest"},{"key":"14471_CR45","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.bbrc.2015.05.083","volume":"463","author":"J Huang","year":"2015","unstructured":"Huang, J. et al. The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-\/-) murine model of ovarian cancer. Biochem Biophys. Res Commun. 463, 551\u2013556 (2015).","journal-title":"Biochem Biophys. Res Commun."},{"key":"14471_CR46","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.4049\/jimmunol.1700467","volume":"200","author":"H Khong","year":"2018","unstructured":"Khong, H. et al. Peptide vaccine formulation controls the duration of antigen presentation and magnitude of tumor-specific CD8(+) T cell response. J. Immunol. 200, 3464\u20133474 (2018).","journal-title":"J. Immunol."},{"key":"14471_CR47","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.stemcr.2015.07.009","volume":"5","author":"CH Chang","year":"2015","unstructured":"Chang, C. H. et al. Mammary stem cells and tumor-initiating cells are more resistant to apoptosis and exhibit increased DNA repair activity in response to DNA damage. Stem Cell Rep. 5, 378\u2013391 (2015).","journal-title":"Stem Cell Rep."},{"key":"14471_CR48","first-page":"3519","volume":"9","author":"CJ Creighton","year":"2015","unstructured":"Creighton, C. J. & Huang, S. Reverse phase protein arrays in signaling pathways: a data integration perspective. Drug Des. Devel Ther. 9, 3519\u20133527 (2015).","journal-title":"Drug Des. Devel Ther."},{"key":"14471_CR49","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/ncb3355","volume":"18","author":"T Welte","year":"2016","unstructured":"Welte, T. et al. Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. Nat. Cell Biol. 18, 632\u2013644 (2016).","journal-title":"Nat. Cell Biol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-14471-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-14471-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-14471-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T23:26:48Z","timestamp":1695684408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-14471-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,31]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["14471"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-14471-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,31]]},"assertion":[{"value":"15 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W.W.O., J.Z., M.A., S.V., D.C., and U.H. are current or past employees and shareholders of Nektar Therapeutics. M.E.H. has been a member of the advisory board and M.Sz. served as a consultant for Nektar Therapeutics. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"661"}}